If You’re Short On Time:

• The U.S. Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes.
• The drug led to impressive blood sugar and body weight drops in clinical trials.
• The approval for tirzepatide—which Lilly will market under the brand name Mounjaro—isn’t for weight loss but Type 2 diabetes.
• Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks?